| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment | HTE12 | | |
| Ovarian cancer | QS18 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention | IPG802 | | |
| Digital technologies to support self-management of COPD: early value assessment | HTE19 | | |
| Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |